Amgen

amgen.com
+1 805-447-1000

Amgen Foundation

One Amgen Center Drive
91320-1799 Thousand Oaks
USA
+1 805-447-1000
amgen.com
Profile News

About Amgen

The Amgen Foundation seeks to advance science education, improve quality of care and access for patients, and support resources that create sound communities where Amgen staff members live and work.

Read more about Amgen
Facts about Amgen
  • Industry : Healthcare

News about Amgen

Amgen

24-Oct-2018 | science

Amgen Invests $66 Million In Oxford Nanopore Technologies

Amgen and Oxford Nanopore Technologies Ltd. announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK- ...

Read news
Amgen

22-Dec-2015 | business & finance

Amgen acquires Medigene spin-off Catherex

Medigene AG announced that Amgen Inc., USA, will acquire 100% of Catherex, Inc., USA, a spin-off of Medigene. As a main shareholder of Catherex, Medigene ...

Read news
Amgen

20-Jul-2012 | business & finance

Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab

Synthon announced that it has entered into a global license agreement with Amgen Inc. and Watson Pharmaceuticals, Inc. for Synthon’s trastuzumab, being ...

Read news
Amgen

05-Apr-2012 | research and development

UCB and Amgen Initiate Sclerostin Antibody Phase 3 program in patients with postmenopausal osteoporosis

First Patient Randomized Marks Start of Phase 3 Program to Evaluate Safety and Efficacy of CDP7851/AMG 785 in Women With Postmenopausal Osteoporosis

Read news
Amgen

01-Mar-2012 | business & finance

Amgen and European Schoolnet Launch New Professional Development Initiative for Life Science Teachers

Program Will Help Increase Student Interest and Achievements in Science in France, Germany, Ireland and Poland

Read news
Amgen

31-Jan-2012 | business & finance

Amgen to Acquire Micromet

All-Cash Transaction Values Micromet at $1.16 Billion

Read news
Amgen

15-Jul-2011 | business & finance

Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen

Maximum deal value of EUR 695 million plus royalties and development cost reimbursement

Read news
Amgen

28-Apr-2011 | research and development

UCB and Amgen announce positive phase 2 results of CDP7851/AMG785 in patients with post menopausal osteoporosis (PMO)

UCB  and Amgen announced positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody CDP7851/AMG785 to placebo in postmenopaus ...

Read news
Show more news about Amgen

Here you will find Amgen Foundation